-
Mashup Score: 19Clinical utility of circulating tumor DNA in patients with advanced KRASG12C-mutated non-small cell lung cancer treated with sotorasib. - 5 day(s) ago
For patients with KRASG12C-mutated NSCLC who are treated with sotorasib, there is a lack of biomarkers to guide treatment decisions. We therefore investigated the clinical utility of pre-treatment and on-treatment circulating tumor DNA (ctDNA), as well as treatment-emergent alterations upon disease progression.
Source: www.jto.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 73
We report long-term outcomes from a pooled analysis of patients with previously untreated metastatic non‒small-cell lung cancer (NSCLC) with programmed cell death ligand 1 (PD-L1) tumor proportion score (TPS) <1% enrolled in phase 3 studies of pembrolizumab plus chemotherapy versus placebo plus chemotherapy.
Source: www.jto.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 1
ESMO is Europe’s leading medical oncology society, providing a professional network for its members and working with national societies across Europe.
Source: www.esmo.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 72
We report long-term outcomes from a pooled analysis of patients with previously untreated metastatic non‒small-cell lung cancer (NSCLC) with programmed cell death ligand 1 (PD-L1) tumor proportion score (TPS) <1% enrolled in phase 3 studies of pembrolizumab plus chemotherapy versus placebo plus chemotherapy.
Source: www.jto.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 46Sotorasib Is a Pan-RASG12C Inhibitor Capable of Driving Clinical Response in NRASG12C Cancers - 27 day(s) ago
AbstractKRASG12C inhibitors, like sotorasib and adagrasib, potently and selectively inhibit KRASG12C through a covalent interaction with the mutant cysteine, driving clinical efficacy in KRASG12C tumors. Because amino acid sequences of the three main RAS isoforms—KRAS, NRAS, and HRAS—are highly similar, we hypothesized that some KRASG12C inhibitors might also target NRASG12C and/or HRASG12C, which are less common but critical oncogenic driver mutations in some tumors. Although some inhibitors, like adagrasib, were highly selective for KRASG12C, others also potently inhibited NRASG12C and/or HRASG12C. Notably, sotorasib was five-fold more potent against NRASG12C compared with KRASG12C or HRASG12C. Structural and reciprocal mutagenesis studies suggested that differences in isoform-specific binding are mediated by a single amino acid: Histidine-95 in KRAS (Leucine-95 in NRAS). A patient with NRASG12C colorectal cancer treated with sotorasib and the anti-EGFR antibody panitumumab achieved
Source: aacrjournals.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 46Sotorasib Is a Pan-RASG12C Inhibitor Capable of Driving Clinical Response in NRASG12C Cancers - 27 day(s) ago
AbstractKRASG12C inhibitors, like sotorasib and adagrasib, potently and selectively inhibit KRASG12C through a covalent interaction with the mutant cysteine, driving clinical efficacy in KRASG12C tumors. Because amino acid sequences of the three main RAS isoforms—KRAS, NRAS, and HRAS—are highly similar, we hypothesized that some KRASG12C inhibitors might also target NRASG12C and/or HRASG12C, which are less common but critical oncogenic driver mutations in some tumors. Although some inhibitors, like adagrasib, were highly selective for KRASG12C, others also potently inhibited NRASG12C and/or HRASG12C. Notably, sotorasib was five-fold more potent against NRASG12C compared with KRASG12C or HRASG12C. Structural and reciprocal mutagenesis studies suggested that differences in isoform-specific binding are mediated by a single amino acid: Histidine-95 in KRAS (Leucine-95 in NRAS). A patient with NRASG12C colorectal cancer treated with sotorasib and the anti-EGFR antibody panitumumab achieved
Source: aacrjournals.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 46Sotorasib Is a Pan-RASG12C Inhibitor Capable of Driving Clinical Response in NRASG12C Cancers - 28 day(s) ago
AbstractKRASG12C inhibitors, like sotorasib and adagrasib, potently and selectively inhibit KRASG12C through a covalent interaction with the mutant cysteine, driving clinical efficacy in KRASG12C tumors. Because amino acid sequences of the three main RAS isoforms—KRAS, NRAS, and HRAS—are highly similar, we hypothesized that some KRASG12C inhibitors might also target NRASG12C and/or HRASG12C, which are less common but critical oncogenic driver mutations in some tumors. Although some inhibitors, like adagrasib, were highly selective for KRASG12C, others also potently inhibited NRASG12C and/or HRASG12C. Notably, sotorasib was five-fold more potent against NRASG12C compared with KRASG12C or HRASG12C. Structural and reciprocal mutagenesis studies suggested that differences in isoform-specific binding are mediated by a single amino acid: Histidine-95 in KRAS (Leucine-95 in NRAS). A patient with NRASG12C colorectal cancer treated with sotorasib and the anti-EGFR antibody panitumumab achieved
Source: aacrjournals.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 50In person registration - 1 month(s) ago
DATE: Friday 12th / Saturday 13th April 2024 VENUE: Johnstown House Hotel, Enfield, Co Meath
Source: docs.google.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 83Detection of tumor DNA in bronchoscopic fluids in peripheral non small cell lung cancer: a proof-of-concept study - 1 month(s) ago
The detection of tumor DNA in the supernatant of guide sheath flush fluid collected during r-EBUS bronchoscopy represents a sensitive and complementary method for genotyping non-small cell lung cancer.
Source: www.jtocrr.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 148Unveiling the Landscape of uncommon EGFR Mutations in Non-Small Cell Lung Cancer - A Systematic Review - 2 month(s) ago
Uncommon EGFR mutations represent a rare subgroup of non-small cell lung cancer. Data on the efficacy of different generations of tyrosine kinase inhibitors (TKIs) in these rare mutations is scattered and limited to mostly retrospective small cohorts, as these patients were usually excluded from clinical trials.
Source: www.jto.orgCategories: General Medicine News, Hem/OncsTweet
ctDNA dynamics in adv KRASG12C+ NSCLC on sotorasib @JTOonline: - Pre-Tx ctDNA+ in 76% (50/66) pts - ctDNA+ pts had ⬇️PFS (HR 2.13 p=0.031) ⬇️OS(HR 2.61 p=0.017) - ⬇️ctDNA at 28d assoc w ⬆️DCR So far, ctDNA appears prognostic @Dingemans_AnneM @OncoAlert https://t.co/RySgyEeccn